周剂量顺铂和奈达铂同步放疗治疗中晚期宫颈癌72例临床分析

目的评价三维适形放疗同步顺铂或奈达铂治疗中晚期宫颈癌患者的近期疗效及不良反应.方法随机将收治的72例组织学明确的中晚期宫颈癌患者分为两组,分别采用顺铂30 mg/m2每周1次或奈达铂30 mg/m2每周1次,两组放疗开始即同步化疗,比较两组患者有效率和副反应发生率.结果顺铂组与奈达铂组的有效率分别为91.7%和94.4%,两组比较无统计学意义(P0.05);顺铂组的胃肠毒性发生率高于奈达铂组(27.8%,11.5%,P0.05);顺铂组的Ⅲ/Ⅳ度骨髓抑制发生率低于奈达铂组(19.4%,30.5%,P0.05).结论周剂量顺铂和奈达铂同步放疗治疗中晚期宫颈癌的近期疗效无差异,副反应均可以耐受.

Clinical Study on 72 Cases of Concurrent Chemoradiotherapy with the Same Dose of Cisplatin Versus Nedaplatin for Advanced Cervical Cancer

Objective To investigate the efficacy and adverse reactions of three dimentional conformal radiation therapy combined with concurrent chemotherapy of cisplatin versus nedaplatin for patients with advanced cervicaI cancer. Method 72 patients with advanced cervical cancer were divided randomly into two groups and treated with a concurrent chemoradiotherapy of cisplatin （30 mg/m^2 one time weekly） or nedaplatin （30 mg/m^2 one time weekly ） with three dimentional conformal radiation therapy. The efficacy and adverse reactions were observed and compared. Results The effective rate of cisplatin and nedapiatin was 91.7% and 94.4% ,respectively,but the difference between both groups was not significant （P 〉 0. 05 ）. The incidence of gastrointestinal toxicity in cisplatin group was higher than that in nedapiatin group （27.8 % , 11.5 % , P〈0.05 ）. However, the incidence of m/Iv myelosuppression in cisplatin group was lower than that in nedapiatin group（ 19.4% ,30.5% ,P〈0.05）. Conclusion The efficacy of combined concurrent chemoradiotherapy of cisplatin or nedaplatin at the same dose is not different significantly and the adverse reactions induced by two treatment regimens are both well-tolerated.